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Challenges in the accurate measurement of sexual behavior in human immunodeficiency virus (HIV) prevention
research are well documented and have prompted discussion about whether valid assessments are possible.
Audio computer-assisted self-interviewing (ACASI) may increase the validity of self-reported behavioral data. In
2006–2007, Zimbabwean women participated in a randomized, cross-sectional study that compared self-reports of
recent vaginal sex and condom use collected through ACASI or face-to-face interviewing (FTFI) with a validated
objective biomarker of recent semen exposure (prostate-specific antigen (PSA) levels). Of 910 study participants,
196 (21.5%) tested positive for PSA, an indication of semen exposure during the previous 2 days. Of these 196
participants, 23 (11.7%) reported no sex in the previous 2 days, with no difference in reported sexual activity
between interview modes (12.5% ACASI vs. 10.9% FTFI; Fisher’s exact test: P ¼ 0.72). In addition, 71 PSA-
positive participants (36.2%) reported condom-protected vaginal sex only; their reports also indicated no difference
between interview modes (33.7% ACASI vs. 39.1% FTFI; P ¼ 0.26). Only 52% of PSA-positive participants
reported unprotected sex during the previous 2 days. Self-report was a poor predictor of recent sexual activity
and condom use in this study, regardless of interview mode, providing evidence that such data should be inter-
preted cautiously.
biological markers; condoms; data collection; epidemiologic measurements; HIV; prostate-specific antigen; sexual
behavior
Abbreviations: ACASI, audio computer-assisted self-interviewing; FTFI, face-to-face interviewing; HIV, human immunodeficiency
virus; MIRA, Methods for Improving Reproductive Health in Africa; PSA, prostate-specific antigen.
The challenges of obtaining accurate measures of self-
reported sexual behavior in sexually transmitted infection
and human immunodeficiency virus (HIV) prevention re-
search are well documented. Study participants may provide
inaccurate reports of their sexual behavior for a variety of
reasons, including social desirability bias (e.g., as a result of
repeated counseling messages related to condom and study
product use), poor recall, concerns about being dropped
from the study if they report low levels of sexual activity
or product use, or poorly worded questions or response cat-
egories (1–4). The need for accurate behavioral data re-
mains important for interpreting results from product
effectiveness studies (to differentiate poor adherence from
lack of product efficacy) and for assessing product safety
(5). Furthermore, reliable behavioral outcomes may be
needed to evaluate interventions conducted in settings or
among population groups where disease incidence is low
or where behavior change is the key outcome of interest
(6, 7). Nonetheless, persistent difficulties in collecting ac-
curate behavioral data on sexual activity and condom use
have prompted some investigators to question whether the
collection of valid behavioral data is even possible.
Interviewer-administered assessments are the standard
data collection mode used to ascertain sexual behavior in
sexually transmitted infection or HIV prevention research.
However, researchers have adopted audio computer-assisted
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self-interviewing (ACASI) because it has shown promise in
increasing the accuracy of self-reported behaviors through
the use of a self-administered questionnaire that affords
privacy (by not requiring an interviewer or a written record
of responses). In addition, ACASI can be designed for low-
literacy populations and can accommodate questionnaires
with complex skip patterns (8, 9). Evaluations of ACASI
to date have been designed as comparisons of responses
between data collection modes (e.g., ACASI vs. face-to-face
interviewing (FTFI)), with inferences regarding validity be-
ing based on the assumption that higher reports of sensitive
behaviors are more accurate. Numerous randomized studies,
mostly conducted in the United States, have shown higher
levels of reported risky sex-related behaviors when ACASI
is employed compared with FTFI. However, other studies
have found inconsistent results (lower reports of risky be-
havior with ACASI or no differences between interview
modes) depending on the behavior assessed (10–20). Be-
cause of the lack of a standard in self-report measures, the
use of an objective biomarker of sexual activity is needed
for direct evaluation of the effect of ACASI on the validity
of behavioral assessments.
We conducted a study among Zimbabwean women to
compare the validity of reports of recent vaginal sex (with
and without condoms) as measured by ACASI with the
validity of reports measured by FTFI. We used the detection
of prostate-specific antigen (PSA), a biomarker with high
positive predictive value (21), as the reference standard for
recent semen exposure and hypothesized that ACASI would
yield a lower proportion of discrepant results (e.g., PSA-
positive but no recent sexual activity reported) than FTFI.
MATERIALS AND METHODS
Study design
This study consisted of a cross-sectional assessment of
recent sexual activity and condom use. It was conducted
from December 2006 through June 2007 among a subset
of women who had recently completed participation in the
Methods for Improving Reproductive Health in Africa
(MIRA) Trial. MIRA was a large randomized controlled
trial that examined the protective effects of diaphragms plus
lubricant gel in decreasing susceptibility to HIV. The trial
was conducted among sexually active HIV-negative women
aged 18–49 years at 3 sites in South Africa and Zimbabwe
(22). Women participated in our study a median of
8.8 months (range, 2.5–20.5) after their final MIRA study
visit. Study participants provided a self-obtained vaginal
swab that was tested for PSA and were randomized to com-
plete a short behavioral interview administered through ei-
ther ACASI or FTFI. The interview comprised questionnaire
items similar to those completed during the MIRA trial.
Study participants and data collection
Former MIRA Trial participants from the 2 Zimbabwe
MIRA study clinics in Chitungwiza and Epworth were eli-
gible for participation. Women learned about the PSA study
at their final MIRA study visit, through community out-
reach, or during post-MIRA clinic visits (e.g., visits made
to obtain additional condoms). Women who expressed
interest were encouraged to return to the MIRA clinic to
consent to and enroll in the PSA study. Only nonpregnant
former MIRA participants who had not had a vaginal de-
livery or third-trimester stillbirth in the previous 6 weeks
were eligible for enrollment. All participants gave written
informed consent prior to enrollment in the PSA study.
Institutional review boards at the University of California,
San Francisco, the Medical Research Council of Zimbabwe,
and Family Health International approved the study.
Participants were randomized to either the ACASI group
or the FTFI group by means of sequentially numbered,
sealed opaque envelopes containing randomization assign-
ments. Using their assigned mode of interviewing, partici-
pants answered questions about their sexual activity and
condom use in the past 7 days. They also were asked about
the following problems with condom use: breakage, slip-
page, and spillage. Participants then provided a self-
collected vaginal swab by following instructions developed
for a MIRA ancillary study (designed to examine whether
diaphragm use conferred protection against human papillo-
mavirus) in which most of the PSA study participants had
taken part. Vaginal swabs were air-dried and shipped in
batches to a research laboratory at the University of North
Carolina, Chapel Hill, for PSA testing.
PSA detection
PSA is produced by the prostate gland and secreted into
the urethra during ejaculation. The protein can be detected
in vaginal fluid specimens collected after exposure to semen
and has high positive predictive value (21, 23, 24). PSA
begins to clear from the vaginal fluid promptly after expo-
sure (e.g., PSA is only detectable in an estimated 29% of
women 24 hours after known exposure) and is rarely present
beyond 48 hours after semen exposure (21). Because of the
rapid clearance of PSA, our analysis focused on discrepant
reporting among women who tested PSA-positive only (i.e.,
no report of recent intercourse or condom-protected inter-
course only and a PSA-positive test result). We used the
Abbott Laboratories IMx assay (Abbott Laboratories,
Abbott Park, Illinois) to detect PSA in the vaginal swab
specimens. PSA levels greater than 1.0 ng/mL indicate
semen exposure within the past 48 hours (21).
For recovery of vaginal secretions, each swab was placed
into 3.0 mL of phosphate-buffered saline, incubated at room
temperature for 15–30 minutes, and then agitated and
pressed against the side of the tube to elute the sample. To
avoid including swabs that had not been used to collect
vaginal fluid, we scored vaginal swab eluates from self-
obtained specimens for the presence of epithelial cells. A
small volume of specimen (0.01 mL) was loaded into the
chamber of a hemacytometer and examined at 2003 mag-
nification in a Nikon Labphot 2 light microscope (Nikon
Instruments, Inc., Melville, New York). Epithelial cells were
present in all self-obtained vaginal swab eluates. Vaginal
specimens were then centrifuged at 2503 g for 10 minutes,
and supernatants were removed from cell pellets and stored
at80C until testing. Supernatants (0.20 mL) from vaginal
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swab eluates were tested using the IMx PSA assay accord-
ing to the manufacturer’s instructions. The enzyme immu-
noassay measures PSA concentrations from 0.04 ng/mL
to 50 ng/mL. Samples with initial test results greater than
50 ng/mL were diluted 1:100 with phosphate-buffered
saline and retested to obtain PSA concentrations.
Analysis
The analysis population consisted of participants who
provided a vaginal swab specimen for PSA testing and com-
pleted the sexual behavior interview. Data on participant
sociodemographic characteristics and sexual history were
extracted from the baseline MIRA study visit. We used
chi-squared tests to compare the proportions of women
who reported having vaginal sex and condom-protected vag-
inal sex in the past 2 days via ACASI with the proportions
who reported those activities via FTFI. To compare self-
reported behaviors with PSA test results, we conducted
a 1-sided Fisher’s exact test, on the basis of our hypothesis
that ACASI would yield increased reporting of sensitive
behaviors (i.e., no recent vaginal sex and vaginal sex un-
protected by a condom) and thus lower the proportion of
results that were discrepant with the PSA test results as
compared with FTFI. We established our sample size to
ensure 80% power to detect a 33% reduction in discordance
(reporting no vaginal sex in the previous 2 days but testing
PSA-positive) by ACASI and assumed that the discordance
in the FTFI group would be 20% (1-sided test; a ¼ 0.05).
Our primary endpoint was defined as reporting no sex for
the past 2 days yet testing positive for PSA. Secondary
endpoints included having a PSA-positive test result yet
reporting: 1) only vaginal sex protected by a condom;
2) only vaginal sex protected by a condom that was used
without breakage, slippage, or spillage of semen; and 3) no
vaginal sex in the previous 7 days. To assess the robustness
of our findings to different PSA levels, we evaluated a semi-
quantitative measure by using 4 categories of PSA concen-
tration as evidence of PSA positivity (1.1–5.0 ng/mL,
5.1–25.0 ng/mL, 25.1–100.0 ng/mL, and >100.0 ng/mL).
Our findings for all study endpoints were consistent with
those obtained using the dichotomous cutpoint of
>1.0 ng/mL (i.e., P values remained nonsignificant); there-
fore, we present only the results of the primary analysis.
RESULTS
Study participants
The PSA study included 918 former participants from the
MIRA Trial (36.7% of the MIRA Zimbabwe sample). Ap-
proximately equal numbers of participants were assigned to
the ACASI and FTFI groups. Eight women in the ACASI
arm did not complete their interviews because of loss of
electrical power for several consecutive days at 1 site. Con-
sequently, the analysis population consisted of 910 partici-
pants (450 ACASI and 460 FTFI). At the time of entry into
the MIRA Trial, most PSA study participants were married
(96.6%) and had not completed high school (55.7%). Par-
ticipants reported a mean of 1.3 lifetime sexual partners
(range, 1–5) and a mean age of 18.5 years at first sexual
intercourse (range, 10–28). The baseline characteristics of
women in the ACASI and FTFI groups were similar (Table 1).
Self-reported recent sexual activity
Thirty-four percent of the women (n ¼ 310) reported
having no vaginal sex in the past 2 days, and 36.4%
(n ¼ 331) reported using a condom for all vaginal sex acts
during this period. The proportion ofwomenwho reported no
vaginal sex did not vary between interview modes (34.0%
ACASI vs. 34.4% FTFI; P ¼ 0.48), but the proportion who
reported condom-protected sex only was lower in the ACASI
group than in the FTFI group (32.7% vs. 40.0%; P ¼ 0.01).
PSA detection and discordance between self-reported
behaviors and PSA results
We found 21.5% of participants (n ¼ 196) to be PSA-
positive, and the proportions of PSA-positive results did
not differ by randomization group (P ¼ 0.25). The median
PSA concentration among participants who tested positive
(>1 ng/mL) was 15.7 ng/mL (interquartile range, 5.3–82.6).
The distribution of positive PSA values is depicted in
Figure 1. Twenty-three (11.7%) participants who tested posi-
tive for PSA reported having no vaginal sex in the previous
2 days, and we observed no difference between interview
modes (12.5% ACASI vs. 10.9% FTFI; P ¼ 0.72; Table 2).
Seventy-one (36.2%) participants who tested positive for
PSA reported condom-protected sex only, and no difference
by interview mode was observed (33.7% ACASI vs. 39.1%
FTFI; P ¼ 0.26). Five of these 71 participants experienced
condom breakage (n ¼ 2), slippage (n ¼ 1), or semen spill-
age (n ¼ 2) during this time period; no difference between
interview modes was observed. Thus, reports of condom
problems also did not explain discordant results in general
(the overall level of discordance was reduced from 48% to
45% when these women were excluded) or between the
ACASI and FTFI groups. Finally, among the PSA-positive
participants, 7.7% (n ¼ 15) reported having no vaginal sex
over the prior 7 days. However, the samples were too small
for us to make meaningful comparisons between interview
modes.
DISCUSSION
In this study, we found substantial levels of discrepant
reporting of recent vaginal sex and sex with a condom rel-
ative to the presence of a validated marker of recent semen
exposure. Nearly half of participants with biologic evidence
of recent semen exposure reported either that they had not
had sex (12%) or that they had had condom-protected sex
only (36%) during the previous 2 days. Direct comparison of
self-reports between interview modes in the absence of the
biomarker suggested that ACASI yielded lower reports of
consistent condom use during recent sexual activity—
ostensibly an indication that ACASI had a modest effect
on improving the accuracy of self-reports. Nevertheless, as
compared with FTFI, ACASI did not improve the level of
concordance between self-reports and the PSA biomarker
results.
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The high level of discrepant reporting in this study, re-
gardless of interview mode, highlights the question of
whether sufficiently valid self-reported behavioral data can
be obtained in HIV prevention research or in other studies
that rely on reports of sexual activity. Our findings corrob-
orate those from several studies, including 2 that found high
levels of discrepancy between reports of condom use and
PSA positivity among female sex workers in Kenya and
Madagascar (25, 26); 1 that found a substantial discrepancy
between reports of condom use and the presence of Y chro-
mosome in the vagina (another biomarker of recent sexual
behavior) among adolescents in the United States (27); and
another that identified detectable spermatozoa in a substan-
tial proportion of women reporting consistent condom use in
a microbicide clinical trial in South Africa (28). The con-
sistency of apparent overreporting of condom use or under-
reporting of sexual activity (even with ACASI data
collection (27)), as corroborated by the presence of a bio-
marker of recent sexual activity, is worthy of further explo-
ration. These results point to several possible explanations,
including perceived stigma or social desirability bias asso-
ciated with admitting nonadherence to HIV prevention strat-
egies (e.g., condom use, partner reduction, or product use in
a microbicide trial) that may prompt intentional misreport-
ing (29); poor recall, even of recent sexual activity; complex
sexual behavior that cannot be captured using standard
quantitative instruments (30); or poorly worded questions
that can be misinterpreted by study participants.
Table 1. Sociodemographic Characteristics, Reproductive History,
and Self-Reported Sexual Behaviora Among 910 Sexually Active






No. % No. %
Age, years
18–24 131 29.1 157 34.1
25–34 219 48.7 215 46.8
35 100 22.2 88 19.1
Education
Less than high school 253 56.2 254 55.2
High school or more 197 43.8 206 44.8
Earned income in
past year
Yes 335 74.4 360 78.3
No 115 25.6 100 21.7
Married
Yes 438 97.3 441 95.9
No 12 2.7 19 4.1
Mean lifetime no. of
sexual partners
(range)
1.3 (1–5) 1.3 (1–4)
Mean age at first
sexual intercourse,
years (range)
18.5 (10–28) 18.5 (13–28)
Coital frequency, no.
of times per week
3 238 52.9 255 55.4




Yes 33 7.3 30 6.5
No 417 92.7 430 93.5
Tested positive for herpes
simplex virus type 2c
Yes 238 53.1 239 52.0







No. % No. %
High behaviorial riskd
Yes 107 23.8 117 25.4
No 343 76.2 343 74.6
Condom use in
past 3 months
Never 122 27.1 131 28.5
Sometimes 199 44.2 206 44.8







11 2.4 17 3.7
Injectable hormones 63 14.0 67 14.6
Oral contraceptives 279 62.0 293 63.7
Male or female
condoms
58 12.9 55 12.0





216 48.0 226 49.1
Condom-only 234 52.0 234 50.9
Abbreviations: ACASI, audio computer-assisted self-interviewing;
FTFI, face-to-face interviewing; MIRA, Methods for Improving Repro-
ductive Health in Africa.
a Measured at baseline for the MIRA Trial.
b At least 1 positive test for Neisseria gonorrhoeae, Chlamydia
trachomatis, or Trichomonas vaginalis at baseline in the MIRA Trial.
c Data on herpes simplex virus type 2 status were missing for 2
subjects because of missing laboratory test results.
d At least 1 of the following: any exchange of sex for money, food,
drugs, or shelter; 2 sexual partners within the past 3 months; having
vaginal sex under the influence of drugs or alcohol in the past 3
months; ever using a needle for injectable drug use; and ever having
anal sex.
e Participants were classified on the basis of the most effective
method reported.
Biomarker Validation of Reported Sexual Behavior 921
Am J Epidemiol 2009;170:918–924
Given these seemingly intractable problems with behav-
ioral assessments of sexual activity, particularly condom
use, should we simply conclude that such data cannot be
collected at all? In part this depends upon the research ques-
tions being investigated and the availability of adequate bio-
markers for assessing the behaviors of interest. A biomarker
like PSA detects only recent semen exposure and constitutes
a measure distinct from those that assess condom-use
behaviors more thoroughly. Because of user errors and me-
chanical failures, some exposure to semen does occur with
condom use (31–33), although that did not seem to influence
results here. Future in-depth qualitative interviews (which
we were not able to conduct) with study participants for
whom discrepancies between PSA test results and self-
reported sexual behavior were identified might aid in the
interpretation of these findings and guide subsequent deci-
sions on questionnaire wording and on the influence of tech-
nological innovations like ACASI.
Several issues should be noted in interpreting our find-
ings. First, although PSA has proven to be a valid biomarker
of recent semen exposure (21), low levels of PSA could in
fact reflect false-positive results due to specimen contami-
nation (34). However, the proportions of discrepant responses
overall, and between ACASI and FTFI, were comparable
when we examined a semiquantitative measure of PSA that
permitted comparison at 4 PSA concentrations, indicating
that our results are robust to the PSA cutpoint chosen. Sec-
ond, because our measure of consistent and correct condom
use was incomplete (in that we did not evaluate the timing of
use and whether condoms may have been applied following
onset of genital contact or removed prior to ejaculation), we
might have overestimated the level of discrepant results for
a minority of participants who may have used condoms but
did so incorrectly. Previous studies suggest that these prob-
lems may be common (35); however, delayed application of
condoms is unlikely to explain our findings, because PSA
levels in preejaculate are below the threshold we used for
defining PSA positivity (36).
In contrast, it is far more likely that we underestimated
the overall prevalence of discrepant results (and possible
misreporting) in our study population because of the rapid
decay curve for PSA (21), which generally is not detectable
after 24 hours for the majority of samples. As a result, some
participants who reported no sexual activity over the last
2 days may have had recent intercourse but with enough
lead time for their PSA result to be negative. Even if this
had occurred, it is unlikely that this underestimation would
differ between the randomized groups, and thus it cannot
explain the lack of difference between interview modes.
Finally, because reporting of sexual history and other sen-
sitive behaviors probably varies across populations and set-
tings, our findings may have limited generalizability for
measuring the utility of ACASI as compared with FTFI,
especially given that women in the study had all previously
participated in an HIV prevention trial.
In this study, ACASI did not improve the validity of re-
ports of recent sexual activity and condom use over FTFI
based on comparison of self-reports with a validated bio-
marker of semen exposure. Overall levels of discordance
between self-reports of sexual behavior and the presence
of a PSA biomarker were high. These findings underscore
the limitations of relying exclusively on self-reported sexual
behavioral data and highlight the need for cautious interpre-
tation of behavioral data on condom use collected using
current approaches. Objective biologic measures of sexual
activity and product use (37) that can be employed in re-
search that requires valid assessments of sexual activity are
urgently needed.
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Figure 1. Distribution of prostate-specific antigen (PSA) concentra-
tions among 910 sexually active women who completed an interview
about sexual activity and condom use in the past 7 days, Prostate-
Specific Antigen Study, Zimbabwe, 2006–2007. PSA concentrations
greater than 1.0 ng/mL were considered as providing evidence of
semen exposure within the past 2 days.
Table 2. Biomarker Validation (by PSA Testinga) of Reports of
Sexual Activity and Condom Use Among Sexually Active Womenb,










No. % No. % No. %
No vaginal sex 13 12.5 10 10.9 23 11.7 0.72
Sex protected by
a male or female
condom only
35 33.7 36 39.1 71 36.2 0.26
Total 48 46.2 46 50.0 94 48.0 0.35
Abbreviations: ACASI, audio computer-assisted self-interviewing;
FTFI, face-to-face interviewing; PSA, prostate-specific antigen.
a PSA concentrations greater than 1.0 ng/mL were considered as
providing evidence of semen exposure within the past 2 days.
b Analysis was restricted to the subset of women (n ¼ 196) who
tested positive for PSA (>1 ng/mL) in vaginal eluate.
c 1-sided Fisher’s exact test.
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